Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

EMA Accepts Marketing Application for T-DXd in HER2-Low and -Ultralow Metastatic Breast Cancer

August 19th 2024

The EMA has validated a type II variation application for trastuzumab deruxtecan for select patients with HER2-low or -ultralow metastatic breast cancer.

EMA Validates Application for Liso-Cel in Relapsed/Refractory Follicular Lymphoma

August 19th 2024

The EMA has expanded the indication for lisocabtagene maraleucel to include the treatment of patients with relapsed or refractory follicular lymphoma.

Copper Depletion Combats Metastatic Recurrence in High-Risk TNBC

August 17th 2024

Linda T. Vahdat, MD, discusses research with copper depletion in patients with high-risk triple-negative breast cancer.

Retrospective Study Reveals Enzalutamide Yields More Favorable Outcomes vs Abiraterone in mCRPC

August 16th 2024

Enzalutamide led to improved OS, PCS, TTS, and TTR vs abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

FDA Grants Fast Track Status to AC699 for ER+/HER2–, ESR1-Mutated Breast Cancer

August 14th 2024

AC699 has won fast track designation from the FDA for select patients with ER-positive, HER2-negative, ESR1-mutated breast cancer.

Vebreltinib Induces Responses in non-CNS MET Fusion+ Solid Tumors

August 13th 2024

Vebreltinib demonstrated preliminary activity in patients with non–central nervous system solid tumors harboring MET fusions.

Toripalimab sNDA Under Review in China for Frontline Unresectable or Metastatic Melanoma

August 13th 2024

A sNDA seeking the approval of toripalimab for frontline use in patients with unresectable or metastatic melanoma is under review by the NMPA.

Devimistat Plus Modified FFX Misses the Mark in Metastatic Pancreatic Adenocarcinoma

August 12th 2024

Devimistat and modified fluorouracil, oxaliplatin, irinotecan, and leucovorin did not significantly improve short- or long-term outcomes over standard-dose FFX in metastatic pancreatic adenocarcinoma

Trastuzumab Deruxtecan Demonstrates Activity in HER2-Expressing Biliary Tract Cancer

August 10th 2024

Trastuzumab deruxtecan elicited responses in patients with HER2-positive biliary tract cancer, according to data from a single-arm, phase 2 trial.

Communication Is Key for Prioritizing Patients and Personalizing PDAC Care

August 9th 2024

Tilak Sundaresan, MD, and Nicole S. Evans, MD, discuss the implications of a study evaluating reasons for non-treatment among patients with PDAC.

Isatuximab Plus VRd Improves PFS in Transplant-Eligible, Newly Diagnosed Myeloma

August 8th 2024

Isatuximab plus VRd induction improved progression-free survival in transplant-eligible, newly diagnosed multiple myeloma.

Leveraging ADCs in Lung Cancer: Snapshot of Existing Challenges and Opportunities

August 7th 2024

Kashul Parikh, MBBS, discusses research efforts dedicated to leveraging antibody-drug conjugates with varying targets in lung cancer.

Real-World Study Reveals Reasons for Pancreatic Cancer Non-Treatment

August 7th 2024

Tilak Sundaresan, MD, and Nicole S. Evans, MD, discuss common reasons for nontreatment among patients with pancreatic cancer.

FDA Clears Companion Diagnostic for Afami-Cel in Pretreated Metastatic Synovial Sarcoma

August 6th 2024

The FDA cleared the SeCore CDx HLA A Sequencing System as a companion diagnostic for afamitresgene autoleucel in advanced synovial sarcoma.

Pirtobrutinib Produces Responses in BTK Inhibitor–Naive R/R CLL/SLL

August 6th 2024

Pirtobrutinib generated responses in BTK inhibitor–naive relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

FDA Awards Orphan Drug Designation to Avutometinib Plus Defactinib in Pancreatic Cancer

August 2nd 2024

The FDA granted an orphan drug designation to the combination of avutometinib and defactinib for use as a potential therapeutic option in patients with pancreatic cancer.

FDA Approves Subcutaneous Daratumumab Plus VRd in Multiple Myeloma

July 30th 2024

The FDA approved Darzalex Faspro plus VRd for induction and consolidation in select patients with newly diagnosed multiple myeloma.

Pembrolizumab Plus Chemo Elicits Responses in Head and Neck Squamous Cell Carcinoma

July 27th 2024

Frontline pembrolizumab, carboplatin, and paclitaxel demonstrated antitumor activity in recurrent or metastatic head and neck squamous cell carcinoma.

Zolbetuximab Plus Chemo Approaches EU Approval for Advanced Gastric/GEJ Cancer

July 26th 2024

The EMA's CHMP has recommended zolbetuximab plus chemotherapy in select locally advanced unresectable or metastatic HER2-negative gastric or GEJ cancer.

NICE Recommends Pembrolizumab Plus Chemo for Untreated HER2– Advanced Gastric/GEJ Adenocarcinoma

July 26th 2024

NICE recommends pembrolizumab plus platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric or GEJ adenocarcinoma.